12:00 AM
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Signifor pasireotide regulatory update

Germany's Federal Joint Committee (G-BA) issued a final assessment that said Cushing's disease drug Signifor pasireotide from Novartis provides a "marginal" degree of additional benefit for patients with Cushing's disease for whom surgery is not an option or has failed - its approved indication. Novartis will now negotiate a price for the Orphan drug,...

Read the full 248 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >